-
Gadolinium Contrast Agents Side Effects: Medical Literature Review, September 2018 – February 2019
Researchers Continue To Investigate Gadolinium Deposition Disease (GDD) Following Gadolinium-Based Contrast Agents Injections (Posted by Tom Lamb at DrugInjuryWatch.com) In recent years it has been recognized that the gadolinium contained in certain…
-
Xeljanz Recommended Dosage For Ulcerative Colitis Patients May Increase Risk Of Pulmonary Embolism
FDA Is Reviewing Safety Of Xeljanz 10 mg Twice-Daily Dose Of This JAK Inhibitor, According to February 2019 News Reports (Posted by Tom Lamb at DrugInjuryWatch.com) UPDATE: FDA Drug Safety Communication: "Safety…
-
Breast Implants Lymphoma Cancer Cases Updates For United States And Canada: February 2019
Additional Cases Of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) Reported To FDA, Health Canada (Posted by Tom Lamb at DrugInjuryWatch.com) For our first 2019 update about breast implant-associated anaplastic large cell…
-
Januvia, Onglyza, Other Diabetes Drugs In DPP-4 Inhibitor Class Significantly Increase Risk Of Crohn’s Disease (CD)
But Same Medical Study Finds That DPP-4 Inhibitors Do Not Increase Risk Of Inflammatory Bowel Disease (IBD) (Posted by Tom Lamb at DrugInjuryWatch.com) Back in March 2018 we wrote this report, “Januvia,…
-
Uloric Recall, “Black-Box Warning”, And Limited Use Discussed By FDA Advisory Committees In January 2019
Despite Drug Safety Problem Of Cardiovascular Mortality, Benefits Might Be Seen To Outweigh Risks For Select Gout Patients (Posted by Tom Lamb at DrugInjuryWatch.com) Uloric (febuxostat) was approved by the FDA in…
